Access to anti-retroviral drugs, female in Algeria

Algeria: Access to anti-retroviral drugs, female was 65.0% in 2024. ◆ Volatile

Latest (2024)
65.0%
Change on year
down 4.4%
World rank
91st
of 141 countries
All-time high
72.0%
in 2019
All-time low
4.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, female in Algeria, 2000–2024

0204060802000201220242000: 4 %2001: 5 %2002: 5 %2003: 5 %2004: 4 %2005: 6 %2006: 7 %2007: 8 %2008: 8 %2009: 15 %2010: 22 %2011: 24 %2012: 27 %2013: 37 %2014: 45 %2015: 53 %2016: 61 %2017: 65 %2018: 69 %2019: 72 %2020: 71 %2021: 72 %2022: 67 %2023: 68 %2024: 65 %

Source: UNAIDS estimates. Measured in %.

Analysis

Algeria recorded 65.0% for access to anti-retroviral drugs, female in 2024.

Compared with earlier readings it is down 4.4% on the previous year and up 44.4% over ten years.

Over the whole period, access to anti-retroviral drugs, female in Algeria peaked at 72.0% in 2019 and was at its lowest, 4.0%, in 2000.

Algeria ranks 91st of 141 countries on this measure, in the middle of the range.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, female in Algeria, year by year

Annual values for Access to anti-retroviral drugs, female (%) in Algeria, 2000 to 2024.
Year % Change
2000 4.0%
2001 5.0% +25.0%
2002 5.0% +0.0%
2003 5.0% +0.0%
2004 4.0% -20.0%
2005 6.0% +50.0%
2006 7.0% +16.7%
2007 8.0% +14.3%
2008 8.0% +0.0%
2009 15.0% +87.5%
2010 22.0% +46.7%
2011 24.0% +9.1%
2012 27.0% +12.5%
2013 37.0% +37.0%
2014 45.0% +21.6%
2015 53.0% +17.8%
2016 61.0% +15.1%
2017 65.0% +6.6%
2018 69.0% +6.2%
2019 72.0% +4.3%
2020 71.0% -1.4%
2021 72.0% +1.4%
2022 67.0% -6.9%
2023 68.0% +1.5%
2024 65.0% -4.4%

Averages by decade

DecadeAverage LowestHighest Years
2000s 6.7% 4.0% 15.0% 10
2010s 47.5% 22.0% 72.0% 10
2020s 68.6% 65.0% 72.0% 5

Countries ranked near Algeria

  1. 88 Barbados 67.0% compare
  2. 88 Iraq 67.0% compare
  3. 88 Jordan 67.0% compare
  4. 91 Costa Rica 65.0% compare
  5. 91 Malaysia 65.0% compare
  6. 91 Montenegro 65.0% compare

See the full ranking of 160 places →

More gender data for Algeria

All data for Algeria →

Frequently asked questions

What is access to anti-retroviral drugs, female in Algeria?
Access to anti-retroviral drugs, female in Algeria was 65.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, female recorded in Algeria?
The highest recorded value was 72.0% in 2019.
What is the lowest access to anti-retroviral drugs, female recorded in Algeria?
The lowest recorded value was 4.0% in 2000.
How does Algeria rank for access to anti-retroviral drugs, female?
Algeria ranks 91st out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, female rising or falling in Algeria?
Over the last ten years it is up 44.4%. The long-run trend across the full record is volatile.
Where does this Algeria data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, female (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, female in Algeria. Statizoid, drawing on UNAIDS estimates. Retrieved 09 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/algeria/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/algeria/">Access to anti-retroviral drugs, female in Algeria</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, female (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,925 data points, 2000–2024
Last refreshed

The percentage of adult females living with HIV who are receiving antiretroviral therapy.